Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

DSMB recommends discontinuation of phase III study of PREOB for osteonecrosis

Nov. 7, 2018

Corcept Therapeutics enrolling participants in phase III study of relacorilant

Nov. 7, 2018

Fat and fibroblasts

Nov. 7, 2018

REWIND study of Trulicity meets primary efficacy objective

Nov. 6, 2018

A 20p11.2 deletion including FOXA2 causes hyperinsulinemic hypoglycemia

Nov. 5, 2018

First mouse model of Costello syndrome highlights role of altered metabolism in disease

Nov. 5, 2018

BioSpecifics reports topline phase I data for CCH in uterine fibroids

Nov. 2, 2018

AEB-4104 prevents death and reverses liver pathology in mouse model of homocystinuria

Nov. 2, 2018

FDA approves Invokana to reduce risk of CV events in adults with type 2 diabetes and CV disease

Oct. 31, 2018

FDA approves Bijuva for moderate to severe hot flashes due to menopause

Oct. 30, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.